Data as of Q4 2025 (Dec 31, 2025)

Opaleye Management Inc.

โ€ขCIK: 1595855โ€ขFiling: Q4 2025

**Opaleye Management Inc.** manages $758M across a portfolio of 54 positions. The firm maintains significant exposure to technology and growth names, highlighted by the top holding in HROW at $191.3M. Other key allocations include LQDA at $85.0M and ETON at $48.4M, indicating a concentrated, conviction-driven approach. This positioning suggests a focus on high-beta, sector-specific opportunities within its mandate.

Total AUM
$758.0M
QoQ Performance
+7.9%
Positions
54
Top 10 Concentration
65.5%
Latest Filing
Q4 2025

Top Holdings Allocation

HROW
LQDA
ETON
HROW25.2%
LQDA11.2%
ETON6.4%
RYTM4.7%
APGE3.9%
SNWV3.9%
STOK2.9%
OCUL2.6%

๐Ÿ“ˆ Biggest Buys

โ€”
CRESCENT BIOPHARMA INC
NEW
1.8% of portfolio
ACOG
ALPHA COGNITION INC
+1698.5%
1.8% of portfolio
RZLT
REZOLUTE INC
+595.9%
2.0% of portfolio
โ€”
SOL GEL TECHNOLOGIES
+121.5%
2.5% of portfolio
KPTI
KARYOPHARM THERAPEUTICS INC
NEW
0.9% of portfolio

๐Ÿ“‰ Biggest Sells

RYTM
RHYTHM PHARMACEUTICALS INC
-28.5%
4.7% of portfolio
CDXS
CODEXIS INC
-46.9%
1.5% of portfolio
LQDA
LIQUIDIA CORPORATION
-6.9%
11.2% of portfolio
ALMS
ALUMIS INC
-19.5%
0.7% of portfolio
TRVI
TREVI THERAPEUTICS INC
-11.5%
0.6% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

IMNM
IMMUNOME INC
SOLD
$37.3M
SRPT
SAREPTA THERAPEUTICS INC
SOLD
$11.3M
LRMR
LARIMAR THERAPEUTICS INC
SOLD
$10.6M
ARVN
ARVINAS INC
SOLD
$8.4M
TMCI
TREACE MEDICAL CONCEPTS INC
SOLD
$4.7M
+4 more exited positions

Changes from Q3 2025

NEW21 new positions
โ†‘16 increased
โ†“7 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023